![Neil Torres](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Neil Torres
Directeur/Bestuurslid bij
Systems Oncology LLC
Profiel
Neil Torres is currently the Director at Systems Oncology LLC and Principal at The Pritzker Organization LLC since 2002.
Mr. Torres completed undergraduate education at The University of Chicago in 2002.
Actieve functies van Neil Torres
| Bedrijven | Functie | Begin |
|---|---|---|
Systems Oncology LLC
 Systems Oncology LLC BiotechnologyHealth Technology Researches and develops cancer drugs | Directeur/Bestuurslid | - |
The Pritzker Organization LLC
 The Pritzker Organization LLC Investment ManagersFinance The Pritzker Organization invests in companies located in the United States with an enterprise value of USD 100 - 1000 billion and an EBITDA of USD 10 - 150 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for growth stage capital requirements with an investment size of USD 75 -300 million for majority deals & USD 15 - 100 million for minority and structured deals. The firm also acquires majority and minority interest. | Private Equity Investor | 01-06-2002 |
Opleiding van Neil Torres
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
98
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pritzker Organization LLC
The Pritzker Organization LLC Investment ManagersFinance The Pritzker Organization invests in companies located in the United States with an enterprise value of USD 100 - 1000 billion and an EBITDA of USD 10 - 150 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for growth stage capital requirements with an investment size of USD 75 -300 million for majority deals & USD 15 - 100 million for minority and structured deals. The firm also acquires majority and minority interest. | Finance |
Systems Oncology LLC
Systems Oncology LLC BiotechnologyHealth Technology Researches and develops cancer drugs | Health Technology |
